glp-1 medication weight loss plateau strategies What Happens After Loss? Struggling with GLP-1 Weight Loss?
Description
The obesity transition: stages of the global epidemic
Whilst most patients experience weight reduction as a secondary benefit, some individuals report unexpected weight gain during treatment, which can be both frustrating and concerning
Clinical Trial Highlights - GLP-1 agonists
It is therefore implausible that short-term GLP-1 RA exposure alone would initiate de novo malignancy within a 1-year timeframe, particularly when considering even shorter exposure periods
The three-to-five year outlook for this category is very high
